# CNPPD1

## Overview
CNPPD1 is a gene that encodes the protein cyclin Pas1/PHO80 domain containing 1, which is categorized as an atypical cyclin. Atypical cyclins, unlike classical cyclins, do not follow the traditional cell cycle regulation patterns and are often involved in diverse cellular processes. The CNPPD1 protein is implicated in various cellular functions, although its precise roles remain to be fully elucidated. Notably, CNPPD1 has garnered attention in cancer research due to its deregulated expression in multiple cancer types, suggesting a potential role in tumorigenesis and as a prognostic marker (Quandt2020Atypical). Additionally, CNPPD1 has been identified as a potential neoantigen in certain cancers, such as lymph node-positive breast cancer, indicating its possible utility in therapeutic strategies, including vaccine development (Quandt2020Atypical). Further research is needed to fully understand the functional dynamics of CNPPD1 and its implications in cancer biology.

## Clinical Significance
CNPPD1, an atypical cyclin, has been implicated in cancer pathogenesis due to its deregulated expression in various cancer types. The expression of CNPPD1 can be either upregulated or downregulated depending on the tissue type, indicating a context-dependent role in cancer (Quandt2020Atypical). This deregulation suggests that CNPPD1 may contribute to tumor heterogeneity and could serve as a prognostic marker. Although CNPPD1 was excluded from protein expression analysis due to technical limitations, its potential role in cancer remains significant, warranting further research to validate its clinical implications (Quandt2020Atypical).

In therapeutic contexts, CNPPD1 has been identified as a potential neoantigen in lymph node-positive breast cancers, suggesting its utility as a vaccine target (Quandt2020Atypical). This highlights the clinical significance of alterations in CNPPD1 expression or interactions, particularly in breast cancer. The challenges in targeting atypical cyclins like CNPPD1 for cancer treatment are notable due to their poorly characterized functions and interactions. However, strategies such as disrupting CDK-cyclin interactions or using antisense oligonucleotides are being explored to address these challenges (Quandt2020Atypical).


## References


[1. (Quandt2020Atypical) Eva Quandt, Mariana P.C. Ribeiro, and Josep Clotet. Atypical cyclins in cancer: new kids on the block? Seminars in Cell &amp; Developmental Biology, 107:46â€“53, November 2020. URL: http://dx.doi.org/10.1016/j.semcdb.2020.04.018, doi:10.1016/j.semcdb.2020.04.018. This article has 2 citations.](https://doi.org/10.1016/j.semcdb.2020.04.018)